Matinas BioPharma Holdings (MTNB) Cash from Financing Activities (2013 - 2025)
Matinas BioPharma Holdings (MTNB) reported Cash from Financing Activities of $58000.0 for Q4 2025, up 5900.0% year-over-year from $966.67 in Q4 2024, and down 9.38% quarter-over-quarter from $64000.0 in Q3 2025.
Matinas BioPharma Holdings (MTNB) Cash from Financing Activities (2013 - 2025) Analysis & Trends
Matinas BioPharma Holdings (MTNB) has 12 years of Cash from Financing Activities data on file, last reported at $58000.0 in Q4 2025.
- Cash from Financing Activities for Q4 2025 came in at $58000.0, up 5900.0% year-over-year; the trailing twelve-month figure through Dec 2025 was $3.4 million (down 63.04% YoY), and the FY2025 annual result was $3.4 million, down 63.04% from the prior year.
- Cash from Financing Activities fell to $58000.0 in Q4 2025 per MTNB's latest filing, from $64000.0 in the prior quarter.
- Over five years, Cash from Financing Activities peaked at $9.2 million in Q2 2024 and troughed at -$67000.0 in Q3 2024.
- A 5-year average of $980100.0 and a median of $3665.0 in 2021 frame the typical range for Cash from Financing Activities.
- On a YoY basis, Cash from Financing Activities climbed as much as 919000.0% in 2024 and fell as far as 6600.0% in 2024.
- A 5-year view of Cash from Financing Activities shows it stood at $8330.0 in 2021, then plunged by 160.02% to -$5000.0 in 2022, then surged by 80.0% to -$1000.0 in 2023, then changed by 0.0% to -$1000.0 in 2024, then surged by 5900.0% to $58000.0 in 2025.
- Business Quant data shows MTNB's Cash from Financing Activities at $58000.0 in Q4 2025, $64000.0 in Q3 2025, and $1.6 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 7.00 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -600,000.00 |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 53,000.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | -538.80 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 85,464.43 |
| 10 | Matinas BioPharma Holdings | 4.60 Mn | 2.15 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 58,000.00 |
| Dec 31, 2025 | 58,000.00 |
| Sep 30, 2025 | 64,000.00 |
| Sep 30, 2025 | 64,000.00 |
| Jun 30, 2025 | 1.62 Mn |
| Jun 30, 2025 | 1.62 Mn |
| Mar 31, 2025 | 1.65 Mn |
| Mar 31, 2025 | 1.65 Mn |
| Dec 31, 2024 | -1,000.00 |
| Dec 31, 2024 | -1,000.00 |
| Sep 30, 2024 | -67,000.00 |
| Sep 30, 2024 | -67,000.00 |
| Jun 30, 2024 | 9.19 Mn |
| Jun 30, 2024 | 9.19 Mn |
| Mar 31, 2024 | 53,000.00 |
| Mar 31, 2024 | 53,000.00 |
| Dec 31, 2023 | -1,000.00 |
| Dec 31, 2023 | -1,000.00 |
| Sep 30, 2023 | -1,000.00 |
| Sep 30, 2023 | -1,000.00 |